ASCO 2022 | 3-year DFS in randomized trials of chemotherapy and HER2-targeted therapy

Abhenil Mittal, MD, DM, Princess Margaret Cancer Center, Toronto, Canada, discusses the findings from a meta-analysis evaluating disease-free (DFS) survival in randomized trials of chemotherapy and HER2-targeted therapy. 3-year DFS for patients with residual disease and HER2-targeted therapy is better than reported in the KATHERINE trial (NCT01772472) evaluating trastuzumab emtansine in HER2- positive early breast cancer and has improved over time, possibly due to increased use of dual HER2-targeted therapy in the neoadjuvant setting This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.